NCT03934372 2025-12-17Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsIncyte CorporationPhase 1/2 Recruiting70 enrolled
NCT04188405 2025-11-20Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer CenterPhase 2 Active not recruiting20 enrolled